Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

USLM vs UTMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UTMD Captures Overall Composite Edge (52.9 HOLD vs 46.1 HOLD), While USLM Leads 4–2 on Growth & Valuation Pillars

UTMD Overall Winner 6-Pillar Tally: USLM 4 – 2 UTMD Matrix Metrics: USLM 5 – 5 UTMD

As of Nov 16, 2026, Utah Medical Products Inc (UTMD) captures the overall head-to-head institutional edge over United States Lime & Minerals (USLM) on higher Unified Composite conviction (52.9/100 HOLD vs. 46.1/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, R&D & Supply-Chain Moat), while USLM wins 4–2 across the 6-pillar growth and valuation breakdown. USLM trades at $107.20 (18.5x Forward P/E, 41.2% operating margin) versus UTMD at $72.38 (13.0x Forward P/E, 34.3% operating margin).

  • Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. USLM 46.1/100 HOLD) and 0.23β · 33% Vol risk profile, whereas USLM leads top-line expansion (+4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: USLM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile UTMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About USLM vs UTMD
USLM NASDAQ
United States Lime & Minerals
Mining & Quarrying Of Nonmetallic Minerals (No Fuels)
$107.20
-3.58% 1D
Market Cap $3.3B
TTM Revenue $381M
Forward P/E 18.5x
Beta / 30D Vol 0.74β · 42% Vol
Unified Composite Score
46.1 / 100 HOLD
Tech 25.0 Fund 42.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.5%), weak momentum, RSI 39
RSI-14: 39.2 · SMA20: $113.99 · SMA50: $112.55
UTMD NASDAQ Head-to-Head Winner
Utah Medical Products Inc
Surgical & Medical Instruments & Apparatus
$72.38
+0.57% 1D
Market Cap $209.6M
TTM Revenue $35M
Forward P/E 13.0x
Beta / 30D Vol 0.23β · 33% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 46.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 50
RSI-14: 49.9 · SMA20: $72.12 · SMA50: $73.04

6-Pillar Scorecard Institutional Category Breakdown (USLM 4 – 2 UTMD)

Columns: Metric · USLM · UTMD
1. Valuation Multiples UTMD
Forward P/E 18.5x 13.0x
Trailing P/E 24.6x 22.0x
PEG Ratio N/M 4.25x
EV / Revenue 8.6x 6.0x
2. Growth & Scale USLM
Revenue Growth (YoY) +4.1% -12.1%
Earnings Growth (YoY) -2.2% +6.8%
TTM Revenue (USD) $381M $35M
Market Cap $3.3B $209.6M
3. Profitability & Quality USLM
Gross Margin 54.4% 57.7%
Operating Margin 41.2% 34.3%
Net Profit Margin 35.1% 30.5%
Return on Equity (ROE) 20.0% 8.8%
4. Balance Sheet & Cash Flow USLM
Cash Generation (TTM) $183M EBITDA $13M EBITDA
Cash Flow Margin 48.1% EBITDA Mgn 38.3% EBITDA Mgn
Net Cash / Leverage $25.64 Book/Sh · 20.0% ROE $38.83 Book/Sh · 8.8% ROE
Dividend Yield 0.21% 0.42%
5. Options & Positioning USLM
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 46.5% (7th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat UTMD
OpEx & R&D Intensity 13.2% of Rev ($50M) 23.4% of Rev ($8.2M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Building Materials Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: USLM (5) vs UTMD (5)
Institutional Metric USLM UTMD Criterion Row Edge
Market Capitalization
Scale
$3.3B $209.6M Larger Scale USLM
Trailing P/E Ratio
Valuation
24.6x 22.0x Lower Multiple UTMD
Forward P/E Ratio
Valuation
18.5x 13.0x Lower Multiple UTMD
Revenue Growth (YoY)
Growth
+4.1% -12.1% Higher Growth USLM
Operating Margin (TTM)
Profitability
41.2% 34.3% Higher Margin USLM
Net Profit Margin
Profitability
35.1% 30.5% Higher Margin USLM
Return on Equity (ROE)
Capital Efficiency
20.0% 8.8% Higher ROE USLM
52-Week Range Position
Momentum
24% ($96–$141) 81% ($54–$77) Stronger Trend UTMD
Beta / 30D Volatility
Risk Regime
0.74β · 42% Vol 0.23β · 33% Vol Lower Realized Risk UTMD
Unified Institutional Score
Composite Signal
46.1 / 100 (HOLD) 52.9 / 100 (HOLD) Higher Composite UTMD
Trailing 12M Revenue (USD)
Operating Scale
$381M $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
54.4% 57.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.6x EV/Rev 4.25x PEG · 6.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$183M EBITDA ($25.64 Book/Sh · 20.0% ROE) $13M EBITDA ($38.83 Book/Sh · 8.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon USLM +3.94 pp
USLM: +1.08% · UTMD: -2.86%
3M Horizon UTMD +9.61 pp
USLM: -9.08% · UTMD: +0.53%
6M Horizon UTMD +10.33 pp
USLM: +2.76% · UTMD: +13.09%
1Y Horizon UTMD +38.67 pp
USLM: -9.67% · UTMD: +29.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on USLM vs UTMD. Trailing 12-month operating profitability (USLM 41.2% vs UTMD 34.3%) and valuation multiples (USLM 18.5x vs UTMD 13.0x Forward P/E) are benchmarked directly in Pillar 4 below.

USLM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$381M
Gross Margin54.4%
Op. Margin41.2%
ROE / Fwd P/E20.0% · 18.5x
UTMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin57.7%
Op. Margin34.3%
ROE / Fwd P/E8.8% · 13.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
USLM CONSOLIDATION
59d in phase · OBV DISTRIBUTION
Current IV 46.5%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact USLM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UTMD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UTMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
USLM Moat Profile High-Margin Pricing Power Moat
Building Materials Operator
Competes within the Building Materials value chain with $3.3B market capitalization and 41.2% operating margin.
OpEx & R&D Reinvestment 13.2% of Rev ($50M)
90D Engineering Disclosures 0 Published
UTMD Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $209.6M market capitalization and 34.3% operating margin.
OpEx & R&D Reinvestment 23.4% of Rev ($8.2M)
90D Engineering Disclosures 0 Published

Investor FAQ USLM vs UTMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Utah Medical Products Inc (UTMD) captures the overall head-to-head institutional edge over United States Lime & Minerals (USLM) on higher Unified Composite conviction (52.9/100 HOLD vs. 46.1/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, R&D & Supply-Chain Moat), while USLM wins 4–2 across the 6-pillar growth and valuation breakdown. USLM trades at $107.20 (18.5x Forward P/E, 41.2% operating margin) versus UTMD at $72.38 (13.0x Forward P/E, 34.3% operating margin). Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. USLM 46.1/100 HOLD) and 0.23β · 33% Vol risk profile, whereas USLM leads top-line expansion (+4.1% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: USLM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile UTMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

USLM leads the Growth & Scale pillar: USLM posts +4.1% YoY revenue growth and -2.2% YoY earnings growth on $381M TTM revenue (54.4% gross margin, 41.2% operating margin), compared with UTMD at -12.1% YoY revenue growth and +6.8% YoY earnings growth on $35M TTM revenue (57.7% gross margin, 34.3% operating margin). On trailing 12-month operating scale, USLM generates $381M in USD-normalized revenue versus $35M for UTMD. In operating R&D and SG&A reinvestment, USLM deploys 13.2% of Rev ($50M) (0 90-day corporate R&D disclosures) versus 23.4% of Rev ($8.2M) (0 disclosures) for UTMD.

UTMD screens cheaper on headline valuation multiples. USLM trades at 18.5x Forward P/E, 24.6x Trailing P/E, N/M PEG, and 8.6x EV/Revenue (48.1% EBITDA margin), whereas UTMD trades at 13.0x Forward P/E, 22.0x Trailing P/E, 4.25x PEG, and 6.0x EV/Revenue (38.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against USLM (20.0% ROE) versus UTMD (8.8% ROE) capital efficiency.

In options market volatility and institutional positioning, USLM carries 46.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.74β · 42% Vol realized risk). By comparison, UTMD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.23β · 33% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.